Plasma Etoposide Catechol Increases in Pediatric Patients Undergoing Multiple-Day Chemotherapy with Etoposide

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 2977-2985

  Zheng, Naiyu ^a,d   Felix, Carolyn A ^a,b   Pang, Shaokun ^a,e   Boston, Ray ^c   Moate, Peter ^c   Scavuzzo, Jennifer ^b   Blair, Ian A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e PURDUE PHARMA L P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL; DRUG METABOLITE; ETOPOSIDE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; EWING SARCOMA; FEMALE; GENOTOXICITY; HODGKIN DISEASE; HUMAN; LEUKEMIA; LIQUID CHROMATOGRAPHY; MALE; MULTIPLE DRUG DOSE; NONHODGKIN LYMPHOMA; PEDIATRICS; PRIORITY JOURNAL; RISK REDUCTION; SCHOOL CHILD; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CATECHOLS; CHILD; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASMS; SARCOMA, EWING'S; TIME FACTORS;

EID: 2442616994     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0221     Document Type: Article

References (49)

1. Henwood JM, Brogden RN. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 1990;39:438-90.
2. Ratain MJ, Kaminer LS, Bitran JD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987;70: 1412-7.
3. Smith MA, Rubenstein L, Cazenave L, et al. Report of the Clinical Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natl Cancer Inst 1993;85:554-8.
4. Smith MA, Rubenstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 1994;23:86-98.
5. Felix CA. Leukemias Related to Treatment with DNA Topoisomerase II Inhibitors. Med Pediatr Oncol 2001;36:525-35.
6. Smith MA, Rubenstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-77.
7. Pui C-H, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Eng J Med 1991;325:1682-7.
8. Kushner BH, Heller G, Cheung N-KV, et al. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol 1998;16:3016-20.
9. Relling MV, Evans R, Dass C, Desiderio DM, Nemec J. Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 1992;261:491-6.
10. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994;45:352-8.
11. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-81.
12. van Maanen JM, Lafleur MV, Mans DR, et al. Effects of the ortho-quinone and catechol of the antitumor drug VP-16-213 on the biological activity of single-stranded and double-stranded φX174 DNA. Biochem Pharmacol 1988;37:3579-89.
13. Mans DRA, Retel J, van Maanen JMS, et al. Role of the semiquinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded φX174 DNA. Br J Cancer 1990;62:54-60.
14. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. Role of quinones in toxicology. Chem Res Toxicol 2000;13:135-60.
15. Haim N, Nemec J, Roman J, Sinha BK. In vitro metabolism of etoposide (VP-16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins. Biochem Pharmacol 1987;36:527-36.
16. van Maanen JM, de Ruiter C, Kootstra PR, et al. Inactivation of φX174 DNA by the ortho-quinone derivative or its reduction product of the antitumor agent VP16-213. Eur J Cancer Clin Oncol 1985;21: 1215-8.
17. van Maanen JM, de Vries J, Pappie D, et al. Cytochrome P-450-mediated O-demethylation: A route in the metabolic activation of etoposide (VP-16-213). Cancer Res 1987;47:4658-62.
18. Demple B, Harrison L. Repair of oxidative damage to DNA: Enzymology and biology. Annu Rev Biochem 1994;63:915-48.
19. Blair IA. Lipid hydroperoxide-mediated DNA damage. Exp Gerontol 2001;36:1473-81.
20. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/ religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 1989;28:6157-60.
21. Osheroff N, Zechiedrich EL, Gale KC. Catalytic function of DNA topoisomerase II. BioEssays 1991;13:269-75.
22. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res and Molecular Biology 2000;64:221-53.
23. Gantchev TG, Hunting DJ. Inhibition of the topoisomerase II-DNA cleavable complex by the ortho- quinone derivative of the antitumor drug etoposide (VP-16). Biochem Biophys Res Commun 1997;237: 24-7.
24. Gantchev TG, Hunting DJ. The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol Pharmacol 1998;53:422-8.
25. Lovett BD, Strumberg D, Blair IA, et al. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 2001;40:1159-70.
26. Lovett BD, Lo Nigro L, Rappaport EF, et al. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc Natl Acad Sci USA 2001;98:9802-7.
27. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7:1333-40.
28. van der Gaast A, Vlastuin M, Kok TC, Splinter TA. What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 × 100 mg, 2 × 50 mg, and 4 × 25 mg of oral etoposide daily for 21 days Semin Oncol 1992;19: 8-12.
29. Funke I, Wiesneth M, Platow S, Kubanek B. Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients. Ann Hematol 2000;79:132-7.
30. van Maanen JM, Retel J, de Vries J, Pinedo HM. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 1988; 80:1526-33.
31. Pang S, Zheng N, Felix CA, Boston R, Blair IA. Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. J Mass Spec 2001;36:771-81.
32. Greif P, Wastney M, Linares O, Boston R. Balancing needs, efficiency, and functionality in the provision of modeling software: a perspective of the NIH WinSAAM Project. Adv Exp Med Biol 1998; 445:3-20.
33. Guyton AC. Partition of body fluids: osmotic equilibria between extracellular and intracellular fluids. In: Textbook of Medical Physiology, Ed. 5. Philadelphia: WB Saunders Co., 1997. p. 424-437.
34. Lowis SP, Pearson AD, Newell DR, Cole M. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res 1993;53:4881-9.
35. Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, Rivera G. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemother Pharmacol 1982;7:147-50.
36. Crom WR, Glynn-Barnhart AM, Rodman JH, et al. Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet 1987;12: 168-213.
37. van de Poll ME, Relling MV, Schuetz EG, Harrison PL, Hughes W, Flynn PM. The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2001;47:467-72.
38. Relling MV, McLeod HL, Bowman LC, Santana VM. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther 1994;56:503-11.
39. Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998;12:346-52.
40. Stremetzne S, Jaehde U, Kasper R, Beyer J, Siegert W, Schunack W. Considerable plasma levels of a cytotoxic etoposide metabolite in patients undergoing high-dose chemotherapy [letter]. Eur J Cancer 1997;33:978-9.
41. Liu B, Earl HM, Poole CJ, Dunn J, Kerr DJ. Etoposide protein binding in cancer patients. Cancer Chemother Pharmacol 1995;36: 506-12.
42. Stewart CF, Arbuck SG, Fleming RA, Evans WE. Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 1991;50:385-93.
43. Schuetz E, Lan L, Yasuda K, et al. Development of a real-time in vivo transcription assay: Application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol Pharmacol 2002;62:439-45.
44. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391.
45. Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997;57:1946-54.
46. Sandler ES, Friedman DJ, Mustafa MM, Winick NJ, Bowman WP, Buchanan GR. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer 1997;79:1049-54.
47. Pui C-H, Relling MV, Rivera GK, et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 1995;9:1990-6.
48. Megonigal MD, Cheung NK, Rappaport EF, et al. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci USA 2000;97:2814-9.
49. Blanco JG, Dervieux T, Edick MJ, et al. Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2001;98:10338-43.